Reality Check on Parkinson's Disease
Market access for Parkinson's disease treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 45% of the lives under commercial formularies are covered without utilization management restrictions
- Class Trends: In June 2018, the FDA approved 34 mgcapsule and 10 mg tablet formulations for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
- Key Findings: Given the number of generic orals, management of the remaining name-brand oral products is restrictive but less so than in other classes. With many strong orals available, understanding how restrictions translate (or don't) to brand-name products is critical
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.